All In Biotech

Drug Trial Radar · NCT06465472

Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Sep 23, 2026

Primary completion

Aug 2030

Study completion Aug 2030

Sponsor

Lead sponsor
BiocodexIndustry
Sponsor type
Industry
Collaborators
Exystat
First posted
Jun 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluation of the efficacy and safety of stiripentol in patients 6 years and older with primary hyperoxaluria type 1, 2 or 3.

Conditions

  • Primary Hyperoxaluria Type 1
  • Primary Hyperoxaluria Type 2
  • Primary Hyperoxaluria Type 3

Interventions

  • Stiripentol Oral CapsuleDrug

    The target dose of stiripentol will be 50 mg/kg/day with a maximum dose of 3,000 mg/day. Patients allocated to the Stiripentol group will receive this treatment during the first 6 months, and in continuation up to 12 months.

  • Placebo Oral CapsuleDrug

    Placebo capsules will be administered for the first 6 months. Then patients will switch to stiripentol over the 6- to 12-month period.

  • Urine samples collectBiological

    Collections of urine over 24 hours and the first urine in the morning (spot urines) will be carried out. Urine collections will be performed either during hospitalizations, or at home if appropriate conditions are met.

  • Blood samples collectBiological

    Series of blood samples will be taken (serum pregnancy test, Primary Hyperoxaluria genetic characterization, clinical laboratory assessments, vitamin B6 dosage, plasma oxalate dosage, stiripentol pharmacokinetics)

  • Kidney imagingOther

    Kidney imaging will be obtained. Renal ultrasounds will be compulsory for all patients.

  • Quality of Life questionnairesOther

    Kidney Disease Quality of Life Questionnaire : KDQOL-36 for patients ≥18 years of age at screening, and the Pediatric Quality of Life Inventory (PedsQL) including the generic and KF modules (parent and/or self-report versions) for patients \<18 years of age at screening. EQ-5D: a standardized instrument consisting of a questionnaire and a visual analog scale pertaining to 5 dimensions. Scoring of the questionnaire is based on degrees of disability. Scoring of the visual analog scale is based on a visual scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). Higher scores indicate better health status. The EQ-5D-5L questionnaire (will be utilized in patients ≥18 years of age at screening, and the EQ-5D-Y questionnaire will be utilized in patients \<18 years of age at screening, where available.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. % change in 24-hour urinary oxalate excretion corrected for body surface area (BSA) determined from 24-hour urine sample collectionsTime frame: % change in 24-hour urinary oxalate excretion between baseline value and value at month 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hôpital Tenon

    Paris, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.